TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean duration of incident HPV infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Endothelium-dependent vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Levels of vascular cell adhesion molecule-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean total caregiver burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Improvement in C5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in C6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant difference on the ABC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: focal myometrial contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inadequate images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post‐bronchodilator FEV(1) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total symptom score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sICAM-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sVCAM-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma non-high-density lipoprotein (non-HDL) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: liver cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fecal cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of violent aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy for avoiding fighting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Assessment of Chronic Illness Care (PACIC) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of keratinized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of spasticity (CSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of standing and walking (GMFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of atrophic epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: stroma/gland ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radial artery occlusion (RAO) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Incidence of grade 1 hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Need for clamp retightening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Worsening of tricuspid regurgitation (TR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Worsening of mitral regurgitation (MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erectile function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral embolic events
Endpoint domain: Adverse events/effects
Primary endpoint: severe bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: API score stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additive pharmacodynamic interaction at 1 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supra-additivity in DSST results at 4 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Focal inflammatory infiltrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Caries progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in glucose maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in insulin maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants asked to give sputum for TB investigation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Need for medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: P wave duration (Pmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood levels of growth hormone (GH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Blood levels of insulin‐like growth factor (IGF‐1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Immune response-related gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDA contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CK-MB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cTnl levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart re-skip rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported improvement and deterioration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: abnormal antenatal monitoring results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy Eating Index 2015 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonadherence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic status improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional status improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Glucose infusion rate (GIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: S-insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MAC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal cooperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment rate of participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SF-36 scale points increase
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: global pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum haemoglobin drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in attitudes towards organ donation advocacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in behavior intentions towards organ donation advocacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time spent reading to babies
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occlusive coronary events
Endpoint domain: Mortality/survival
Primary endpoint: Other cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Ischaemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Allergen provocation test reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HCMV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of pediatric ICU stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: extubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvements in triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: APOB/APOA1 ratio improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transfusion of blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin percentage (Hb%) after 6 h and 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum‐25(OH) vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum‐1,25(OH)₂ vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin secretion (c‐peptide levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in facial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in endoscopically-assessed mucosal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uGAG excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic assessment of sinonasal cavities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean lifetime cumulative attachment loss (LCAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average levels of TGF-beta1 in GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discussion of advance directives
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Completion of advance directive forms
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in ISI scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Decrease in use of sleep medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in mood ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in KT width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NIHSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean blood flow velocity (MFVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gosling pulsatility index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Temperature change in facial areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRQOL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: depressive relapse/recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of postoperative airway related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of adjustment and positioning after laryngeal mask placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest laryngeal mask intralaryngeal pressure for ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 improvement at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Waist circumference (WC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bone alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in bone structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance cycle performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hs-CRP value reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of AQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of AQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma levels of MPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the MPA concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responsiveness of the CAP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of plausible alternative hypotheses
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in core symptoms of DG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceleration of gastric emptying (GE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adenoma detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Caecal intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HAQ mean scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FACIT-Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: SF-36 Summary Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 3-year relapse-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 3-year pelvic control rate
Endpoint domain: Mortality/survival
Primary endpoint: peak blood-ethanol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: puffs per cigarette
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interpuff intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNPT improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of chest compressions with adequate depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of oxidative damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Decline in visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Il‐1beta response to plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GH peak response to GHRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GH AUC response to GHRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Conversational reciprocity performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adult criminal involvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: early and middle adolescent antisocial behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in BCVA of 10 letters or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: erythrocyte deformability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of any adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of multiple adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improved vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of osteonecrosis (ARCO staging)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HHS (Harris Hip Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with measured zinc levels in the normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability of pterygium surgery eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epworth Sleepiness Scale improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Objective wakefulness (modified maintenance of wakefulness test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL subfractions levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HDL2-C/HDL3-C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of obturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PZn levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Zinc deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Contamination rate of atomizers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: EAL gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in glabellar rhytides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in supine systolic BP (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in supine diastolic BP (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consistent condom use
Endpoint domain: Life impact
Endpoint subdomain: Behavioral outcomes
Primary endpoint: Urinary albumin/urinary creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary 8‐OHdG/Cr ratio (U8CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Freedom from pain and allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypotension withdrawal rate
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the use of epidural anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lower rates of episiotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Shorter second stage labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of spontaneous bowel movement (SBM) ≥3 times/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of normalized stool forms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of complete response (no PONV and no rescue antiemetics)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in average daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickening of tendons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR; no emetic episodes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No radiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of gastrointestinal fistulas
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Severity Score (PSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Interference Score (PIS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall sensitivity to detect prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall specificity to detect prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patients' visual analogue scale scores for scar comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' visual analogue scale scores for scar appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes